Search

Your search keyword '"Virgo, Paul"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Virgo, Paul" Remove constraint Author: "Virgo, Paul" Database Supplemental Index Remove constraint Database: Supplemental Index
19 results on '"Virgo, Paul"'

Search Results

1. T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy

2. Sampling endoscopically normal large bowel mucosa from patients presenting with elevated faecal calprotectin levels is not clinically justified

Catalog

Books, media, physical & digital resources

3. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

4. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

5. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage

7. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia

8. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia

9. Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

10. Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

11. Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia

12. Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials

13. Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials

14. Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

15. Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

16. Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively

18. Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia

19. Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia